Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17362859 | 0.74 | TDO2 (0.34) | SSTR4 | |
| SCHEMBL31618227 | 0.74 | SSTR4 (0.34) | SSTR4 | |
| SCHEMBL29257709 | 0.74 | NPC1 (0.36) | — | |
| SCHEMBL30951654 | 0.74 | NPC1 (0.36) | — | |
| SCHEMBL28877694 | 0.71 | NPC1 (0.31) | — | |
| SCHEMBL30050661 | 0.71 | NPC1 (0.31) | — | |
| SCHEMBL30833665 | 0.70 | KMT2A (0.35) | PDE10A | |
| SCHEMBL3310887 | 0.70 | KMT2A (0.35) | PDE10A | |
| SCHEMBL31618413 | 0.69 | SSTR4 (0.42) | SSTR4CYP17A1PDE10A | |
| SCHEMBL17818464 | 0.68 | CYP11B2 (0.32) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585241-A | AT2R antagonists and uses thereof | 伊莱利利公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-03-06 | — | — | US | disclosed |
| US-12122750-B2 | AT2R antagonists and uses thereof | ELI LILLY AND COMPANY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022152705-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | CDC25B 84/4885SSTR4 2682/4885CYP17A1 434/4885 |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | CDC25B 2383/4885SSTR4 155/4885CYP17A1 3270/4885 |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | CDC25B 2360/4885SSTR4 158/4885CYP17A1 3258/4885 |
| US-12122750-B2 | AT2R antagonists and uses thereof | AGTR2, AGTR1, AVPR2 | CDC25B 2383/4885SSTR4 155/4885CYP17A1 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.